Edesa Biotech, Inc. (EDSA) Form 8-K — Nov 9, 2026
Edesa Biotech signed an exclusive collaboration and license agreement with Kyorin Pharmaceutical to develop and commercialize paridiprubart (EB05) for acute respiratory distress syndrome in Japan. Edesa receives a $12 million upfront payment plus up to $55 million in development/regulatory milestones, up to ¥12.0 billion in sales milestones, and double-digit tiered royalties, in a deal the company values at more than $140 million. Edesa retains all rights to paridiprubart outside Japan, including the US, Europe and Canada, and will manufacture and supply product to Kyorin, who funds Japanese development and commercialization.
Key figures
- Deal Value Usd
- more than $140 million in upfront and potential milestones
- Royalty
- low double-digit tiered royalties on Japan net sales
- Licensed asset
- paridiprubart (EB05), anti-TLR4 monoclonal antibody for ARDS
- Phase3 mortality
- adjusted mortality 39% vs 52% placebo, p<0.001; sustained at 60 days (p=0.003)
- Licensed territory
- Japan
- Upfront payment usd
- 12000000
- Sales milestones jpy
- up to ¥12.0 billion (~$80M)
- Total potential value
- more than $140 million including upfront and milestones
- Development regulatory milestones usd
- up to $55 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.